Nosakhare Paul Ilerhunmwuwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nosakhare Paul Ilerhunmwuwa has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Aiwuyo Osarume Henry
Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA
3 shared publications - Beatrice Torere
Internal Medicine, North Mississippi Medical Center, Tupelo, USA
3 shared publications - Jen Chin Wang
Division of Hematology and Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY, USA
3 shared publications Mustafa Wasifuddin
Department of Internal Medicine, One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn, New York, United States of America
3 shared publications- Mustafa Wasifuddin
Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA
3 shared publications Aditya Keerthi Rayapureddy
Department of Internal Medicine, One Brooklyn Health/Interfaith Medical Center, Brooklyn, New York, United States of America
2 shared publications
Latest Publications
- Open Access
- 31 July 2025
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 23 (2) , 148-163
Factors Associated With Pericardial Effusion and Mortality in Renal Cancer Patients
Purpose: This study aims to identify determinants of pericardial effusion (PCE) in patients with renal cancer and predictors of in-hospital mortality in patients with renal cancer and PCE.Materials and Methods: We conducted a retrospective cohort study using National Inpatient Sample of patients with primary malignant renal cancer data from 2016–2020. A total of 85,288 patients were included in the analysis, of which 763 (0.90%) presented with PCE. The main outcomes of interest were the presence of PCE and the in-hospital mortality rate in patients with renal cancer and PCE.Results: The majority of our cohort are aged ≥40 years (96.79%) and males (64.57%). In the bivariate analysis, patients <40 years had higher odds of PCE (adjusted odds ratio [aOR], 1.82; 95% confidence interval [CI], 1.23–2.63). Non-Hispanic Black (aOR, 1.59; 95% CI ,1.30–1.94) and Hispanic patients were associated with an increased odd of PCE odds ratio. Higher Elixhauser comorbidity index (≥4: aOR, 2.27; 95% CI, 1.66–3.08), hypoproteinemia (aOR, 1.49; 95% CI, 1.22–1.81), heart failure (aOR, 2.15; 95% CI 1.83–2.55), metastatic disease (aOR, 1.36; 95% CI, 1.15–1.62), and severe disease presentation (aOR, 6.35; 95% CI, 4.82–8.36) were also significant predictors of PCE. Private insurance was associated with higher PCE odds (aOR, 1.43; 95% CI, 1.20–1.70). Among PCE patients, the in-hospital mortality rate was 13.37%. Self-pay insurance status (aOR, 3.82; 95% CI, 1.05–13.95), metastatic disease (aOR, 1.76; 95% CI, 1.07–2.96), and severe disease presentation (aOR, 3.46; 95% CI, 1.05–8.58) significantly predicted increased mortality.Conclusion: This study identifies crucial demographic, clinical, and healthcare system factors associated with PCE and in-hospital mortality in renal cancer patients. These findings highlight the need for increased vigilance and tailored surveillance for vulnerable groups and those with higher comorbidity burdens.
- 31 July 2025
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 23 (2) , 148-163
Open AccessFactors Associated With Pericardial Effusion and Mortality in Renal Cancer Patients
Purpose: This study aims to identify determinants of pericardial effusion (PCE) in patients with renal cancer and predictors of in-hospital mortality in patients with renal cancer and PCE.Materials and Methods: We conducted a retrospective cohort study using National Inpatient Sample of patients with primary malignant renal cancer data from 2016–2020. A total of 85,288 patients were included in the analysis, of which 763 (0.90%) presented with PCE. The main outcomes of interest were the presence of PCE and the in-hospital mortality rate in patients with renal cancer and PCE.Results: The majority of our cohort are aged ≥40 years (96.79%) and males (64.57%). In the bivariate analysis, patients <40 years had higher odds of PCE (adjusted odds ratio [aOR], 1.82; 95% confidence interval [CI], 1.23–2.63). Non-Hispanic Black (aOR, 1.59; 95% CI ,1.30–1.94) and Hispanic patients were associated with an increased odd of PCE odds ratio. Higher Elixhauser comorbidity index (≥4: aOR, 2.27; 95% CI, 1.66–3.08), hypoproteinemia (aOR, 1.49; 95% CI, 1.22–1.81), heart failure (aOR, 2.15; 95% CI 1.83–2.55), metastatic disease (aOR, 1.36; 95% CI, 1.15–1.62), and severe disease presentation (aOR, 6.35; 95% CI, 4.82–8.36) were also significant predictors of PCE. Private insurance was associated with higher PCE odds (aOR, 1.43; 95% CI, 1.20–1.70). Among PCE patients, the in-hospital mortality rate was 13.37%. Self-pay insurance status (aOR, 3.82; 95% CI, 1.05–13.95), metastatic disease (aOR, 1.76; 95% CI, 1.07–2.96), and severe disease presentation (aOR, 3.46; 95% CI, 1.05–8.58) significantly predicted increased mortality.Conclusion: This study identifies crucial demographic, clinical, and healthcare system factors associated with PCE and in-hospital mortality in renal cancer patients. These findings highlight the need for increased vigilance and tailored surveillance for vulnerable groups and those with higher comorbidity burdens.
- Open Access
- 1 March 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (7) , 1026-1034
Dietary interventions in cancer: a systematic review of all randomized controlled trials
Background: Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic review, we assessed all randomized controlled trials (RCTs) investigating dietary interventions for cancer patients, examining the range of interventions, endpoints, patient populations, and results. Methods: This systematic review identified all RCTs conducted before January 2023 testing dietary interventions in patients with cancer. Assessed outcomes included quality of life, functional outcomes, clinical cancer measurements (eg, progression-free survival, response rates), overall survival, and translational endpoints (eg, inflammatory markers). Results: In total, 252 RCTs were identified involving 31 067 patients. The median sample size was 71 (interquartile range 41 to 118), and 80 (32%) studies had a sample size greater than 100. Most trials (n = 184, 73%) were conducted in the adjuvant setting. Weight or body composition and translational endpoints were the most common primary endpoints (n = 64, 25%; n = 52, 21%, respectively). Direct cancer measurements and overall survival were primary endpoints in 20 (8%) and 7 (3%) studies, respectively. Eight trials with a primary endpoint of cancer measurement (40%) met their endpoint. Large trials in colon (n = 1429), breast (n = 3088), and prostate cancer (n = 478) each showed no effect of dietary interventions on endpoints measuring cancer. Conclusion: Most RCTs of dietary interventions in cancer are small and measure nonclinical endpoints. Although only a small number of large RCTs have been conducted to date, these trials have not shown an improvement in cancer outcomes. Currently, there is limited evidence to support dietary interventions as a therapeutic tool in cancer care.
- 1 March 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (7) , 1026-1034
Open AccessDietary interventions in cancer: a systematic review of all randomized controlled trials
Background: Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic review, we assessed all randomized controlled trials (RCTs) investigating dietary interventions for cancer patients, examining the range of interventions, endpoints, patient populations, and results. Methods: This systematic review identified all RCTs conducted before January 2023 testing dietary interventions in patients with cancer. Assessed outcomes included quality of life, functional outcomes, clinical cancer measurements (eg, progression-free survival, response rates), overall survival, and translational endpoints (eg, inflammatory markers). Results: In total, 252 RCTs were identified involving 31 067 patients. The median sample size was 71 (interquartile range 41 to 118), and 80 (32%) studies had a sample size greater than 100. Most trials (n = 184, 73%) were conducted in the adjuvant setting. Weight or body composition and translational endpoints were the most common primary endpoints (n = 64, 25%; n = 52, 21%, respectively). Direct cancer measurements and overall survival were primary endpoints in 20 (8%) and 7 (3%) studies, respectively. Eight trials with a primary endpoint of cancer measurement (40%) met their endpoint. Large trials in colon (n = 1429), breast (n = 3088), and prostate cancer (n = 478) each showed no effect of dietary interventions on endpoints measuring cancer. Conclusion: Most RCTs of dietary interventions in cancer are small and measure nonclinical endpoints. Although only a small number of large RCTs have been conducted to date, these trials have not shown an improvement in cancer outcomes. Currently, there is limited evidence to support dietary interventions as a therapeutic tool in cancer care.
- Open Access
- 6 August 2023
- Published by Elsevier in Leukemia Research Reports
- Vol. 20, 100383
Characteristics and survival outcomes of patients with atypical chronic myeloid leukemia in the United States: A SEER-based analysis
- 6 August 2023
- Published by Elsevier in Leukemia Research Reports
- Vol. 20, 100383
Open AccessCharacteristics and survival outcomes of patients with atypical chronic myeloid leukemia in the United States: A SEER-based analysis
- 21 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (4) , 611-619
Demographics and outcomes of hemoglobin genotype in hospitalized patients with COVID‐19 and sickle cell disease in the United States
Introduction: Coronavirus disease 2019 (COVID-19) is associated with poor outcomes in sickle cell disease (SCD) patients. However, there is a paucity of data comparing hemoglobin (Hb) genotypes in SCD and infection outcomes. Methods: The National Inpatient Sample was used to identify the record of hospitalizations with COVID-19 and SCD in 2020 using the International Classification of Disease, Tenth Revision codes. Study outcomes (invasive mechanical ventilation, extracorporeal membrane oxygenation, shock, vasopressor use, measures of resource utilization, and in-hospital mortality) were compared between hemoglobin SS, SC, and S-beta thalassemia (S beta). Results: Of the 102 975 COVID-19 hospitalizations with SCD, 87.26% had HbSS, 7.16% had HbSC, and 5.58% had HbS beta. Younger patients were more likely to have HbSS, while older patients were likely to have HbSC and HbS beta. HbSS was more frequent with Blacks, while HbS beta was more prevalent with Whites and Hispanics. Though measures of resource utilization were higher in HbSS, there was no significant difference in in-hospital outcomes between the three genotypes. Conclusion: There is no difference in COVID-19 outcomes among Hb genotypes in SCD. Further studies are needed to explore the reasons for this observation.
- 21 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (4) , 611-619
Demographics and outcomes of hemoglobin genotype in hospitalized patients with COVID‐19 and sickle cell disease in the United States
Introduction: Coronavirus disease 2019 (COVID-19) is associated with poor outcomes in sickle cell disease (SCD) patients. However, there is a paucity of data comparing hemoglobin (Hb) genotypes in SCD and infection outcomes. Methods: The National Inpatient Sample was used to identify the record of hospitalizations with COVID-19 and SCD in 2020 using the International Classification of Disease, Tenth Revision codes. Study outcomes (invasive mechanical ventilation, extracorporeal membrane oxygenation, shock, vasopressor use, measures of resource utilization, and in-hospital mortality) were compared between hemoglobin SS, SC, and S-beta thalassemia (S beta). Results: Of the 102 975 COVID-19 hospitalizations with SCD, 87.26% had HbSS, 7.16% had HbSC, and 5.58% had HbS beta. Younger patients were more likely to have HbSS, while older patients were likely to have HbSC and HbS beta. HbSS was more frequent with Blacks, while HbS beta was more prevalent with Whites and Hispanics. Though measures of resource utilization were higher in HbSS, there was no significant difference in in-hospital outcomes between the three genotypes. Conclusion: There is no difference in COVID-19 outcomes among Hb genotypes in SCD. Further studies are needed to explore the reasons for this observation.
- Open Access
- 29 June 2023
- Published by CARI Journals Limited in International Journal of Health Sciences
- Vol. 6 (4) , 25-37
Inter-Racial Effect on Electrocardiographic Abnormalities among Stroke Patients in Sub-Saharan Africa
Purpose: The study aimed to determine the prevalence of electrocardiographic abnormalities in black stroke patients and to find out if the black race predisposes to increased electrocardiographic abnormalities as well as specific electrocardiographic abnormalities among the study population. Methodology: This was a cross-sectional analytical study carried out at the University of Benin Teaching Hospital Benin. The electrocardiographic abnormalities of one hundred and twenty (120) admitted black stroke patients in this study were compared with Goldstein study on Caucasians in the United States of America. The data were analyzed using the IBM SPSS statistics version 22. A p < 0.05 was considered significant. Results: The study demonstrated the prevalence of electrocardiographic abnormalities among black stroke patients to be 76.6% with the associated presence of left axis deviation (52.17% vs 15.22%, p<0.001), left atrial enlargement (17.39% vs 5.80%, p=0.005) and ST segment depression (43.50% vs 21.74%, p=0.001). On the contrary, stroke patients of the Caucasian race were linked to sinus tachycardia (30.44 % vs 13.04%, p=0.002), prolonged QT (49.28% vs 8.70%, p <0.001) and premature ventricular complex (13.04% vs 4.35%, p =0.049) with a concomitant absence of bi-atrial enlargement, low limb lead voltage and non-specific intraventricular block. They had a prevalence of 92%. Unique Contribution to Theory, Policy and Practice: The prevalence of electrocardiographic abnormalities is lower among the black stroke individuals compared to the Caucasians even though the former tend to present with features of structural abnormalities compared to the latter who had more electrical abnormalities. Therefore, in resource-poor settings where ECG cannot readily be carried out, the race of the patient may guide the clinician in suspecting the probable cardiac changes in stroke patients.
- 29 June 2023
- Published by CARI Journals Limited in International Journal of Health Sciences
- Vol. 6 (4) , 25-37
Open AccessInter-Racial Effect on Electrocardiographic Abnormalities among Stroke Patients in Sub-Saharan Africa
Purpose: The study aimed to determine the prevalence of electrocardiographic abnormalities in black stroke patients and to find out if the black race predisposes to increased electrocardiographic abnormalities as well as specific electrocardiographic abnormalities among the study population. Methodology: This was a cross-sectional analytical study carried out at the University of Benin Teaching Hospital Benin. The electrocardiographic abnormalities of one hundred and twenty (120) admitted black stroke patients in this study were compared with Goldstein study on Caucasians in the United States of America. The data were analyzed using the IBM SPSS statistics version 22. A p < 0.05 was considered significant. Results: The study demonstrated the prevalence of electrocardiographic abnormalities among black stroke patients to be 76.6% with the associated presence of left axis deviation (52.17% vs 15.22%, p<0.001), left atrial enlargement (17.39% vs 5.80%, p=0.005) and ST segment depression (43.50% vs 21.74%, p=0.001). On the contrary, stroke patients of the Caucasian race were linked to sinus tachycardia (30.44 % vs 13.04%, p=0.002), prolonged QT (49.28% vs 8.70%, p <0.001) and premature ventricular complex (13.04% vs 4.35%, p =0.049) with a concomitant absence of bi-atrial enlargement, low limb lead voltage and non-specific intraventricular block. They had a prevalence of 92%. Unique Contribution to Theory, Policy and Practice: The prevalence of electrocardiographic abnormalities is lower among the black stroke individuals compared to the Caucasians even though the former tend to present with features of structural abnormalities compared to the latter who had more electrical abnormalities. Therefore, in resource-poor settings where ECG cannot readily be carried out, the race of the patient may guide the clinician in suspecting the probable cardiac changes in stroke patients.
- Open Access
- 1 June 2023
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 14 (3) , 165-173
Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
- 1 June 2023
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 14 (3) , 165-173
Open AccessPituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
Pituitary Metastases From Differentiated Thyroid Cancers: A Systematic Review
- Open Access
- 7 April 2023
- Published by Archives of Breast Cancer in Archives of Breast Cancer
- p. 210-215
Primary Cutaneous Apocrine Adenocarcinoma of the Axilla in Klinefelter’s Syndrome: A Case Report
Background: Primary Cutaneous Apocrine Adenocarcinoma (PCAA) is a rare cutaneous malignancy that arises from areas rich in apocrine glands, particularly the axilla. There are less than 200 cases described in the literature. However, none has been reported in patients with Klinefelter syndrome, who are known to have an increased risk of breast cancer, Case Presentation: We present a 66-year-old man with a significant family history of breast cancer who developed a right axillary mass initially thought to be hidradenitis suppurativa. On physical examination, he had bilateral gynecomastia. Laboratory workup was significant for hyper-gonadotrophic hypogonadism. Mammography showed bilateral gynecomastia with no radiologic evidence of malignancy in the breast, while magnetic resonance imaging of the breast revealed two suspicious masses seen in the right breast. Excision biopsy of the right axillary mass revealed a high-grade invasive adenocarcinoma involving the dermis and subcutis; the cells had prominent nucleoli vesicular chromatin pattern and voluminous eosinophilic cytoplasm consistent with primary cutaneous apocrine adenocarcinoma. Immunohistochemistry was positive for GATA-3, GCDFP-15, E-cadherin, ER Positive, PR negative, HER 2 by IHC 3 +, and androgen receptor-positive 100 %. Positron emission tomography showed mildly hypermetabolic asymmetric gynecomastia, right greater than left, but no abnormal hypermetabolic activity to suggest malignancy. Karyotype confirmed 47 XXY chromosomes which on. The patient underwent bilateral mastectomy due to his preference; excised breast tissue was negative for malignancy. Conclusion: We presented the first case report of PCAA of axillary in Klinefelter syndrome. Awareness of this association and differentiation from breast carcinoma should be undertaken.
- 7 April 2023
- Published by Archives of Breast Cancer in Archives of Breast Cancer
- p. 210-215
Open AccessPrimary Cutaneous Apocrine Adenocarcinoma of the Axilla in Klinefelter’s Syndrome: A Case Report
Background: Primary Cutaneous Apocrine Adenocarcinoma (PCAA) is a rare cutaneous malignancy that arises from areas rich in apocrine glands, particularly the axilla. There are less than 200 cases described in the literature. However, none has been reported in patients with Klinefelter syndrome, who are known to have an increased risk of breast cancer, Case Presentation: We present a 66-year-old man with a significant family history of breast cancer who developed a right axillary mass initially thought to be hidradenitis suppurativa. On physical examination, he had bilateral gynecomastia. Laboratory workup was significant for hyper-gonadotrophic hypogonadism. Mammography showed bilateral gynecomastia with no radiologic evidence of malignancy in the breast, while magnetic resonance imaging of the breast revealed two suspicious masses seen in the right breast. Excision biopsy of the right axillary mass revealed a high-grade invasive adenocarcinoma involving the dermis and subcutis; the cells had prominent nucleoli vesicular chromatin pattern and voluminous eosinophilic cytoplasm consistent with primary cutaneous apocrine adenocarcinoma. Immunohistochemistry was positive for GATA-3, GCDFP-15, E-cadherin, ER Positive, PR negative, HER 2 by IHC 3 +, and androgen receptor-positive 100 %. Positron emission tomography showed mildly hypermetabolic asymmetric gynecomastia, right greater than left, but no abnormal hypermetabolic activity to suggest malignancy. Karyotype confirmed 47 XXY chromosomes which on. The patient underwent bilateral mastectomy due to his preference; excised breast tissue was negative for malignancy. Conclusion: We presented the first case report of PCAA of axillary in Klinefelter syndrome. Awareness of this association and differentiation from breast carcinoma should be undertaken.
- Open Access
- 30 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e33123
Cardiac Tamponade in Patients With Breast Cancer: A Systematic Review
Cardiac tamponade is a rare presentation in breast cancer and may be associated with poor prognosis. In this article, we reviewed the characteristics and survival outcomes of patients with breast cancer who developed cardiac tamponade. Three databases (PubMed, EMBASE and SCOPUS) were searched for relevant articles published from 1978 to 2022 and 16 articles were identified comprising 64 cases. The median age of the cases was 52 years. Cardiac tamponade was diagnosed with echocardiogram or computerized tomography of the chest or both in 91.9%, 1.6% and 6.5% of the cases, respectively. Cytology of the pericardial fluid was done in 90.5% of the cases while biopsy in addition to cytology was done in 9.5% of cases. Tamponade was proven to be malignant in 97.4% of the cases. The initial treatment for tamponade was pericardiocentesis. Adjunct therapies ranged from the insertion of a pericardial window, pericardiectomy, radiotherapy and chemotherapy. The median time from the first treatment of breast cancer to the onset of tamponade was 24 months while the median survival following diagnosis of tamponade was 13 months. There was no significant correlation (spearman rank-sum correlation coefficient = 0.35, p = 0.165) between time to tamponade (interval time from the first diagnosis of breast cancer and the onset of cardiac tamponade) and survival. Cardiac tamponade may adversely affect survival in patients with breast cancer. Early diagnosis with echocardiogram and cytology may guide management and expectations. Further observational studies are needed to determine the predictors of cardiac tamponade and optimal treatment in patients with breast cancer.
- 30 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e33123
Open AccessCardiac Tamponade in Patients With Breast Cancer: A Systematic Review
Cardiac tamponade is a rare presentation in breast cancer and may be associated with poor prognosis. In this article, we reviewed the characteristics and survival outcomes of patients with breast cancer who developed cardiac tamponade. Three databases (PubMed, EMBASE and SCOPUS) were searched for relevant articles published from 1978 to 2022 and 16 articles were identified comprising 64 cases. The median age of the cases was 52 years. Cardiac tamponade was diagnosed with echocardiogram or computerized tomography of the chest or both in 91.9%, 1.6% and 6.5% of the cases, respectively. Cytology of the pericardial fluid was done in 90.5% of the cases while biopsy in addition to cytology was done in 9.5% of cases. Tamponade was proven to be malignant in 97.4% of the cases. The initial treatment for tamponade was pericardiocentesis. Adjunct therapies ranged from the insertion of a pericardial window, pericardiectomy, radiotherapy and chemotherapy. The median time from the first treatment of breast cancer to the onset of tamponade was 24 months while the median survival following diagnosis of tamponade was 13 months. There was no significant correlation (spearman rank-sum correlation coefficient = 0.35, p = 0.165) between time to tamponade (interval time from the first diagnosis of breast cancer and the onset of cardiac tamponade) and survival. Cardiac tamponade may adversely affect survival in patients with breast cancer. Early diagnosis with echocardiogram and cytology may guide management and expectations. Further observational studies are needed to determine the predictors of cardiac tamponade and optimal treatment in patients with breast cancer.
- Open Access
- 29 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e33085
A Rare Case of Metastatic Gastric Signet Ring Cell Adenocarcinoma in a 23-Year-Old Female Presenting as Malignant Pleural Effusion
Signet ring cell carcinoma (SRCC) is a poorly differentiated mucin-producing adenocarcinoma with greater than 50% signet ring cells. It commonly arises from the gastrointestinal (GI) tract and rarely from extraintestinal organs. This is a rare case of a young African American female who presented with metastatic spread of signet ring cell gastric cancer (pleural and lymph nodal involvement) as the initial presentation of SRCC. Knowledge of the various clinical manifestations of SRCC can help with its early diagnosis, and there is a high need for detailed physical examination, early referral, and prompt treatment in patients with SRCC.
- 29 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e33085
Open AccessA Rare Case of Metastatic Gastric Signet Ring Cell Adenocarcinoma in a 23-Year-Old Female Presenting as Malignant Pleural Effusion
Signet ring cell carcinoma (SRCC) is a poorly differentiated mucin-producing adenocarcinoma with greater than 50% signet ring cells. It commonly arises from the gastrointestinal (GI) tract and rarely from extraintestinal organs. This is a rare case of a young African American female who presented with metastatic spread of signet ring cell gastric cancer (pleural and lymph nodal involvement) as the initial presentation of SRCC. Knowledge of the various clinical manifestations of SRCC can help with its early diagnosis, and there is a high need for detailed physical examination, early referral, and prompt treatment in patients with SRCC.
- Open Access
- 4 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32217
BRASH Syndrome Presenting With Idioventricular Escape Rhythm in a Patient With Trifascicular Block
Bradycardia, renal failure, atrioventricular (AV) nodal disease, shock, and hyperkalemia (BRASH) syndrome is a well-recognized constellation of distinct clinicopathologic entities comprising bradycardia, renal failure, AV nodal disease, shock, and hyperkalemia. Our patient is an 89-year-old female with a past medical history significant for hypertension and diabetes, who was newly started on labetalol and had recent gastroenteritis; she presented to our Emergency Department with bradycardia and shock. Upon presentation, she showed physical signs of volume depletion, and her blood pressure was 50 mmHg systolic and heart rate was 25 beats per minute. The initial electrocardiogram showed an idioventricular rhythm. The laboratory workup revealed hyperkalemia. The patient was given repeated doses of atropine with no significant response. She was resuscitated with isotonic fluids. The patient improved clinically, her blood pressure stabilized, her potassium level, renal function, and heart rate were normalized, and normal sinus rhythm was restored with a narrow QRS complex. A diagnosis of BRASH syndrome was made retrospectively. Overall, the treatment of this syndrome is largely symptomatic. Hemodynamic support with fluid and treatment of hyperkalemia remains the goal of care. The overall prognosis is good if identified early and managed appropriately.
- 4 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32217
Open AccessBRASH Syndrome Presenting With Idioventricular Escape Rhythm in a Patient With Trifascicular Block
Bradycardia, renal failure, atrioventricular (AV) nodal disease, shock, and hyperkalemia (BRASH) syndrome is a well-recognized constellation of distinct clinicopathologic entities comprising bradycardia, renal failure, AV nodal disease, shock, and hyperkalemia. Our patient is an 89-year-old female with a past medical history significant for hypertension and diabetes, who was newly started on labetalol and had recent gastroenteritis; she presented to our Emergency Department with bradycardia and shock. Upon presentation, she showed physical signs of volume depletion, and her blood pressure was 50 mmHg systolic and heart rate was 25 beats per minute. The initial electrocardiogram showed an idioventricular rhythm. The laboratory workup revealed hyperkalemia. The patient was given repeated doses of atropine with no significant response. She was resuscitated with isotonic fluids. The patient improved clinically, her blood pressure stabilized, her potassium level, renal function, and heart rate were normalized, and normal sinus rhythm was restored with a narrow QRS complex. A diagnosis of BRASH syndrome was made retrospectively. Overall, the treatment of this syndrome is largely symptomatic. Hemodynamic support with fluid and treatment of hyperkalemia remains the goal of care. The overall prognosis is good if identified early and managed appropriately.